Tim L. Jansen

Venlo, LI 5912BL, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Gout treat-to-target for whom? - Authors' reply.

Gout treat-to-target for whom? - Authors' reply.

Journal: The Lancet. Rheumatology

Published: May 03, 2026

A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial.

A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial.

Journal: The Lancet. Rheumatology

Published: August 12, 2025

Man with a royal headache and neck pain.

Man with a royal headache and neck pain.

Journal: Emergency medicine journal : EMJ

Published: June 25, 2024

Erosive Hand OsteoArthritis (EHOA): analysis of consecutive patients presenting with EHOA in a hospital-based rheumatology practice and its implications for an upcoming interventional study.

Erosive Hand OsteoArthritis (EHOA): analysis of consecutive patients presenting with EHOA in a hospital-based rheumatology practice and its implications for an upcoming interventional study.

Journal: Clinical rheumatology

Published: December 25, 2021

Hughes-Stovin syndrome (HSS): current status and future perspectives.

Hughes-Stovin syndrome (HSS): current status and future perspectives.

Journal: Clinical rheumatology

Published: September 30, 2021

A historical journey of searching for uricosuric drugs.

A historical journey of searching for uricosuric drugs.

Journal: Clinical rheumatology

Published: July 30, 2021

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

Journal: The Lancet. Rheumatology

Published: October 02, 2020

Clinical image.

Clinical image.

Journal: Clinical rheumatology

Published: January 26, 2020

Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019.

Lessons and pitfalls from the 2020 Gout Clinical Practice Guideline presented in Atlanta at the ACR 2019.

Journal: Clinical rheumatology

Published: January 05, 2020

Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout.

Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout.

Journal: Annals of the rheumatic diseases

Published: August 29, 2019

Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.

Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.

Journal: Clinical rheumatology

Published: November 29, 2018

International position paper on the appropriate use of uricosurics with the introduction of lesinurad.

International position paper on the appropriate use of uricosurics with the introduction of lesinurad.

Journal: Clinical rheumatology

Published: September 13, 2018

Showing 1-12 of 23

Last Updated: 09/26/2026